Currently in the United Kingdom, cardiovascular disease (CVD) risk assessment is based on the QRISK3 score, in which 10% 10-year CVD risk indicates clinical intervention. However, this benchmark has limited efficacy in clinical practice and the need for a more simple, non-invasive risk stratification tool is necessary. Retinal photography is becoming increasingly acceptable as a non-invasive imaging tool for CVD. Previously, we developed a novel CVD risk stratification system based on retinal photographs predicting future CVD risk. This study aims to further validate our biomarker, Reti-CVD, (1) to detect risk group of \u2265\u200910% in 10-year CVD risk and (2) enhance risk assessment in individuals with QRISK3 of 7.5\u201310% (termed as borderline-QRISK3 group) using the UK Biobank.<\/p>\n\n\n\n
Reti-CVD scores were calculated and stratified into three risk groups based on optimized cut-off values from the UK Biobank. We used Cox proportional-hazards models to evaluate the ability of Reti-CVD to predict CVD events in the general population. C-statistics was used to assess the prognostic value of adding Reti-CVD to QRISK3 in borderline-QRISK3 group and three vulnerable subgroups. <\/p>\n\n\n\n
Among 48,260 participants with no history of CVD, 6.3% had CVD events during the 11-year follow-up. Reti-CVD was associated with an increased risk of CVD (adjusted hazard ratio [HR] 1.41; 95% confidence interval [CI], 1.30\u20131.52) with a 13.1% (95% CI, 11.7\u201314.6%) 10-year CVD risk in Reti-CVD-high-risk group. The 10-year CVD risk of the borderline-QRISK3 group was greater than 10% in Reti-CVD-high-risk group (11.5% in non-statin cohort [n<\/em>\u2009=\u200945,473], 11.5% in stage 1 hypertension cohort [n<\/em>\u2009=\u200911,966], and 14.2% in middle-aged cohort [n<\/em>\u2009=\u200938,941]).\u00a0C<\/em>\u00a0statistics increased by 0.014 (0.010\u20130.017) in non-statin cohort, 0.013 (0.007\u20130.019) in stage 1 hypertension cohort, and 0.023 (0.018\u20130.029) in middle-aged cohort for CVD event prediction after adding Reti-CVD to QRISK3.<\/p>\n\n\n\n Reti-CVD has the potential to identify individuals with \u2265\u200910% 10-year CVD risk who are likely to benefit from earlier preventative CVD interventions. For borderline-QRISK3 individuals with 10-year CVD risk between 7.5 and 10%, Reti-CVD could be used as a risk enhancer tool to help improve discernment accuracy, especially in adult groups that may be pre-disposed to CVD.<\/p>\n","protected":false},"template":"","publication_type_categories":[11],"publication_categories":[16],"class_list":["post-1021","publication","type-publication","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/types\/publication"}],"version-history":[{"count":1,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1021\/revisions"}],"predecessor-version":[{"id":1022,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1021\/revisions\/1022"}],"wp:attachment":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/media?parent=1021"}],"wp:term":[{"taxonomy":"publication_type_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_type_categories?post=1021"},{"taxonomy":"publication_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_categories?post=1021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Conclusion<\/h4>\n\n\n\n